Security
MIRA Pharmaceuticals, Inc. Common Stock · MIRA
MIRANASDAQCommon stockCurrentCIK 1904286Updated Oct 29, 2026
Name history
Mira1a Therapeutics, Inc. · through May 2, 2023
MIRA price & chart
Loading TradingView…
NASDAQ:MIRA on TradingView ↗In the news
No coverage from other publishers is available.
Seeking Alpha
SEC disclosures
MIRA PHARMACEUTICALS, INC. files 8-K: Material Event ↗
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 7,633,280Source | 4,266,571Source | 8,203,140Source | 868,318Source | 3,015,578Source | 9,463,736Source | 1,400,338Source | 3,808,791Source | 11,093,605Source | 2,923,099Source | 4,932,443Source | 858,074Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 2,641,539Source | — | 3,609,442Source | 730,475Source | — | 4,815,031Source | 1,206,285Source | — | 6,346,921Source | — | — | — |
| Accounts Receivable | — | — | — | — | — | — | — | — | — | — | —Source | — |
| Assets, CurrentUSD | 7,597,841Source | 4,231,132Source | 8,167,701Source | 832,879Source | 2,932,403Source | 9,428,297Source | 1,364,899Source | 3,714,031Source | 11,058,166Source | 2,887,660Source | 4,858,230Source | 494,405Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 83,926Source | 692,833Source | 40,823Source | 298,459Source | 796,612Source | 114,761Source | 106,173Source | 652,006Source | 702,068Source | 723,349Source | 558,097Source | 1,454,306Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 3,951Source | 1,627Source | 4,202Source | 1,739Source | 1,478Source | 4,202Source | 1,682Source | 1,478Source | 4,194Source | 1,656Source | 1,478Source | 6,657Source |
| Additional Paid in CapitalUSD | 41,142,288Source | 30,310,136Source | 50,097,007Source | 33,027,332Source | 26,911,646Source | 50,075,131Source | 32,213,983Source | 26,158,140Source | 49,967,549Source | 31,335,815Source | 25,657,930Source | 8,699,830Source |
| Retained Earnings (Accumulated Deficit)USD | -33,596,885Source | -26,738,025Source | -41,938,892Source | -32,459,212Source | -24,694,158Source | -40,730,358Source | -30,921,500Source | -23,002,833Source | -39,580,206Source | -29,137,721Source | -21,285,062Source | -9,302,719Source |
| Stockholders' Equity Attributable to ParentUSD | 7,549,354Source | 3,573,737Source | 8,162,317Source | 569,859Source | 2,218,966Source | 9,348,975Source | 1,294,165Source | 3,156,785Source | 10,391,537Source | 2,199,750Source | 4,374,346Source | -596,232Source |
| Liabilities and EquityUSD | 7,633,280Source | 4,266,571Source | 8,203,140Source | 868,318Source | 3,015,578Source | 9,463,736Source | 1,400,338Source | 3,808,791Source | 11,093,605Source | 2,923,099Source | 4,932,443Source | 858,074Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 83,926Source | 692,833Source | 40,823Source | 298,459Source | 796,612Source | 114,761Source | 106,173Source | 652,006Source | 702,068Source | 723,349Source | 558,097Source | 1,370,039Source |
| Accounts Payable, CurrentUSD | 83,926Source | — | 40,823Source | 298,459Source | — | 34,008Source | 100,673Source | 636,261Source | 129,203Source | — | — | — |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 84,267Source |
| Additional Financial Items | ||||||||||||
| Partners' CapitalUSD | — | — | — | — | — | — | — | — | 6,700,000Source | — | — | — |
| Short-term InvestmentsUSD | 4,894,366Source | — | 4,503,973Source | — | — | 4,591,518Source | — | — | 4,683,099Source | — | — | — |
| Operating Lease, Right-of-Use Asset | — | — | — | — | — | — | — | —Source | — | — | — | — |
| Operating Lease, Liability, Current | — | — | — | — | — | — | — | —Source | — | — | — | — |
| Accrued Liabilities, Current | — | — | — | — | — | — | —Source | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 107,590Source | 874,812Source | 6,313,167Source | 1,920,805Source | 2,550,946Source | 1,296,600Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | — | — | — | 11,862Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -1,201,283Source | -1,630,027Source | -4,661,669Source | -5,560,606Source | -4,532,403Source | -5,604,759Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -330,607Source | 3,381Source | 8,175,659Source | 3,790,971Source | 8,783,991Source | 3,146,185Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -1,531,890Source | -1,626,646Source | 3,513,990Source | -1,769,635Source | 4,251,588Source | -2,458,574Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | 21,876Source | 489,566Source | 21,585Source | 874,812Source | 6,100,000Source | 1,900,000Source | — | — |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | — | — | — | — | 732,292Source | — |
| General and Administrative ExpenseUSD | — | — | 904,346Source | 1,014,223Source | 450,330Source | 1,049,903Source | 578,698Source | 1,490,796Source | 8,773,329Source | 4,712,753Source | 6,499,537Source | 2,992,125Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,137,673Source | -2,043,867Source | -1,208,534Source | -1,537,712Source | -1,150,152Source | -1,783,779Source | -10,442,485Source | -7,852,659Source | -11,982,343Source | -7,058,190Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -22,694,494Source | -2,043,867Source | — | — | — | — | -31,999,306Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | 179,312Source | 37,752Source | -52,415Source | 8,388Source | -46,673Source | 21,421Source | 50,627Source | — | — | — |
| Operating ExpensesUSD | — | — | 1,316,985Source | 2,081,619Source | 1,156,119Source | 1,546,100Source | 1,103,479Source | 1,805,200Source | 10,493,112Source | 8,018,328Source | 8,526,049Source | 7,047,940Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | -52,415Source | 8,388Source | -46,673Source | 21,421Source | 50,627Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 3,381Source | 7,006,982Source | 3,608,555Source | 7,704,279Source | 2,904,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | 888,282Source | — | — | — |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | 176,056Source | — | -87,545Source | — | -91,582Source | — | -35,212Source | — | — | — |
| Proceeds from Contributions from Affiliates | — | — | — | — | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other Nonoperating Income (Expense)USD | — | — | — | — | -52,415Source | 8,388Source | -46,673Source | 21,421Source | 50,627Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,137,673Source | -2,043,867Source | -1,208,534Source | -1,537,712Source | -1,150,152Source | -1,783,779Source | -10,442,485Source | -7,852,659Source | -11,982,343Source | -7,058,190Source |
| Earnings Per Share, BasicUSD per share | — | — | -1.18Source | -0.14Source | -0.03Source | -0.09Source | -0.03Source | -0.11Source | -1.35Source | -0.51Source | -0.64Source | -0.4Source |
| Earnings Per Share, DilutedUSD per share | — | — | -1.18Source | -0.14Source | -0.03Source | -0.09Source | -0.03Source | -0.11Source | -1.35Source | -0.51Source | -0.64Source | -0.4Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 19,274,947Source | 15,071,915Source | 42,022,087Source | 16,986,488Source | 41,941,370Source | 16,645,119Source | 23,694,333Source | 15,444,149Source | 18,566,158Source | 17,566,533Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 19,274,947Source | 15,071,915Source | — | 16,986,488Source | — | 16,645,119Source | — | 15,444,149Source | 18,566,158Source | 17,566,533Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 904,346Source | 1,014,223Source | 450,330Source | 1,049,903Source | 578,698Source | 1,490,796Source | 8,773,329Source | 4,712,753Source | 6,499,537Source | 2,992,125Source |
| Interest ExpenseUSD | — | — | — | -37,752Source | — | — | — | -21,421Source | — | -165,669Source | 3,456,294Source | 10,250Source |
| Interest Income (Expense), NetUSD | — | — | 15,697Source | 37,752Source | 35,130Source | 8,623Source | 44,909Source | 21,421Source | 98,911Source | — | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -22,694,494Source | -2,043,867Source | — | — | — | — | -31,999,306Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | 179,312Source | 37,752Source | -52,415Source | 8,388Source | -46,673Source | 21,421Source | 50,627Source | — | — | — |
| Operating ExpensesUSD | — | — | 1,316,985Source | 2,081,619Source | 1,156,119Source | 1,546,100Source | 1,103,479Source | 1,805,200Source | 10,493,112Source | 8,018,328Source | 8,526,049Source | 7,047,940Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | — | 21,556,821Source | — | — | — | — | — | 21,556,821Source | — | — | — |
| Research and Development ExpenseUSD | — | — | 412,639Source | 1,067,396Source | 705,789Source | 496,197Source | 524,781Source | 314,404Source | 1,719,783Source | 3,305,575Source | 1,572,962Source | 2,351,465Source |
Filing attachments
ex99-1.htm · 8-K · 2026-10-28
Exhibit 99.1 MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide SKNY-1’s Weight Reduction Without Significant Changes in Food Consumption Suggests a Potential Role for Energy Expenditure, Contrasting With Semaglutide’s Initial Food-Intake Suppression and Significant Post-Treatment Increase MIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) - MIRA Pharmaceuticals, Inc. (NASDAQ: MI…
Read attachment ↗ex99-1.htm · 8-K · 2026-10-22
Exhibit 99.1 MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study Positive IND-Enabling Proof-of-Concept Study Demonstrates Sustained Efficacy Without Observed Tolerance, Reduced Inflammation-Associated Swelling, and Favorable Tolerability MIAMI, Oct. 22 (GLOBE NEWSWIRE) - MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company developing novel oral therapies for…
Read attachment ↗ex99-1.htm · 8-K · 2026-09-17
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review Protocol Submitted for IRB Review at a Leading Cancer Research Institution, Advancing the Study Toward Site Initiation MIAMI, Sept. 17, 2026 (GLOBE NEWSWIRE) - MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today…
Read attachment ↗ex99-1.htm · 8-K · 2026-09-01
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND Positive Toxicology Results From 7-Day Rat and Dog Studies Characterize Tolerability and Inform Dose Selection for Next Phase of IND-Enabling Program, Targeting Q1 2027 IND Submission MIAMI, Sept. 1, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company developing novel oral small-mo…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-06
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 MIRA Reports Positive 7-Day Dog Study Results for SKNY-1 - Obesity Treatment Designed to Preserve Lean Body Mass Toxicokinetic Findings De-Risk Dose Selection and Support Regulatory Pathway Toward IND MIAMI, August 6, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced positive toxicokinetic findings …
Read attachment ↗ex99-1.htm · 8-K · 2026-07-10
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain Optimized Oral Formulation Demonstrates Favorable Oral Bioavailability Together with Robust Brain and Liver Distribution Following Oral Administration MIAMI, FL / ACCESS Newswire / July 10, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical …
Read attachment ↗